{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:04:49Z","timestamp":1793228689334,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11096-025-01895-2","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T14:58:31Z","timestamp":1742655511000},"page":"1204-1214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative effectiveness of potassium-competitive acid blockers and proton pump inhibitors in dual antiplatelet therapy patients: a nationwide cohort study"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8611-2374","authenticated-orcid":false,"given":"Yu Jeong","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-5131","authenticated-orcid":false,"given":"Nam Kyung","family":"Je","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"10","key":"1895_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2016;68(10):1082\u2013115. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.513.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1895_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419.","journal-title":"Eur Heart J"},{"issue":"3","key":"1895_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000321813","volume":"83","author":"T Tanigawa","year":"2011","unstructured":"Tanigawa T, Watanabe T, Nadatani Y, et al. Gastrointestinal bleeding after percutaneous coronary intervention. Digestion. 2011;83(3):153\u201360. https:\/\/doi.org\/10.1159\/000321813.","journal-title":"Digestion"},{"issue":"10","key":"1895_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.4070\/kcj.2020.0196","volume":"50","author":"HK Kim","year":"2020","unstructured":"Kim HK, Ahn Y, Chang K, et al. 2020 Korean society of myocardial infarction expert consensus document on pharmacotherapy for acute myocardial infarction. Korean Circ J. 2020;50(10):845\u201366. https:\/\/doi.org\/10.4070\/kcj.2020.0196.","journal-title":"Korean Circ J"},{"issue":"38","key":"1895_CR5","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191.","journal-title":"Eur Heart J"},{"issue":"9","key":"1895_CR6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","volume":"82","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American heart Association\/American college of cardiology joint committee on clinical practice guidelines. J Am Coll Cardiol. 2023;82(9):833\u2013955. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.003.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1895_CR7","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jacc.2010.11.024","volume":"57","author":"ER Bates","year":"2011","unstructured":"Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011;57(11):1251\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2010.11.024.","journal-title":"J Am Coll Cardiol"},{"key":"1895_CR8","unstructured":"Plavix In: Drug label (revised 9\/2016) Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020839s062s064lbl.pdf. Accessed 15 Aug 2024."},{"issue":"8","key":"1895_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/17425255.2024.2378888","volume":"20","author":"G Jourdi","year":"2024","unstructured":"Jourdi G, Hulot JS, Gaussem P. An update on oral antiplatelet drug interactions with proton pump inhibitors: what are the risks? Expert Opin Drug Metab Toxicol. 2024;20(8):749\u201364. https:\/\/doi.org\/10.1080\/17425255.2024.2378888.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1895_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.694698","volume":"12","author":"H Guo","year":"2021","unstructured":"Guo H, Ye Z, Huang R. Clinical outcomes of concomitant use of proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. Front Pharmacol. 2021;12: 694698. https:\/\/doi.org\/10.3389\/fphar.2021.694698.","journal-title":"Front Pharmacol"},{"key":"1895_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","volume":"168","author":"N Inatomi","year":"2016","unstructured":"Inatomi N, Matsukawa J, Sakurai Y, et al. Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther. 2016;168:12\u201322. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.08.001.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1895_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40262-023-01228-4","volume":"62","author":"E Yang","year":"2023","unstructured":"Yang E, Ji SC, Jang IJ, et al. Evaluation of CYP2C19-mediated pharmacokinetic drug interaction of Tegoprazan, compared with vonoprazan or esomeprazole. Clin Pharmacokinet. 2023;62(4):599\u2013608. https:\/\/doi.org\/10.1007\/s40262-023-01228-4.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1895_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11894-024-00939-3","volume":"26","author":"C Scarpignato","year":"2024","unstructured":"Scarpignato C, Hunt RH. Potassium-competitive acid blockers: current clinical use and future developments. Curr Gastroenterol Rep. 2024;26(11):273\u201393. https:\/\/doi.org\/10.1007\/s11894-024-00939-3.","journal-title":"Curr Gastroenterol Rep"},{"issue":"6","key":"1895_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5816","volume":"33","author":"Y Lee","year":"2024","unstructured":"Lee Y, Choi HJ, Park S, et al. Temporal trends in use of antisecretory agents among patients administered clopidogrel-based dual antiplatelet therapy after percutaneous coronary intervention. Pharmacoepidemiol Drug Saf. 2024;33(6): e5816. https:\/\/doi.org\/10.1002\/pds.5816.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"1895_CR15","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","volume":"32","author":"J-A Kim","year":"2017","unstructured":"Kim J-A, Yoon S, Kim L-Y, et al. Towards actualizing the value potential of korea health insurance review and assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. 2017;32(5):718\u201328. https:\/\/doi.org\/10.3346\/jkms.2017.32.5.718.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"1895_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264538","volume":"17","author":"J Park","year":"2022","unstructured":"Park J, Jung JH, Choi EK, et al. Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. PLoS ONE. 2022;17(2): e0264538. https:\/\/doi.org\/10.1371\/journal.pone.0264538.","journal-title":"PLoS ONE"},{"issue":"2","key":"1895_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1161\/STROKEAHA.120.030761","volume":"52","author":"S Kwon","year":"2021","unstructured":"Kwon S, Lee SR, Choi EK, et al. Non-Vitamin K Antagonist oral anticoagulants in patients with atrial fibrillation and prior gastrointestinal bleeding. Stroke. 2021;52(2):511\u201320. https:\/\/doi.org\/10.1161\/STROKEAHA.120.030761.","journal-title":"Stroke"},{"issue":"21","key":"1895_CR18","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1016\/j.jacc.2014.02.586","volume":"63","author":"MD Solomon","year":"2014","unstructured":"Solomon MD, Go AS, Shilane D, et al. Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2014;63(21):2249\u201357. https:\/\/doi.org\/10.1016\/j.jacc.2014.02.586.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1895_CR19","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1124\/dmd.111.041293","volume":"39","author":"BW Ogilvie","year":"2011","unstructured":"Ogilvie BW, Yerino P, Kazmi F, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011;39(11):2020\u201333. https:\/\/doi.org\/10.1124\/dmd.111.041293.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"1895_CR20","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1124\/dmd.112.045575","volume":"40","author":"T Zvyaga","year":"2012","unstructured":"Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012;40(9):1698\u2013711. https:\/\/doi.org\/10.1124\/dmd.112.045575.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1895_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.32429\/jkshp.2024.41.2.004","volume":"41","author":"HW Lee","year":"2024","unstructured":"Lee HW, Yu HB, Ko JH, et al. Co-administration of clopidogrel-based DAPT and antisecretory agents: comparison of incidence of cardiovascular events. J Korean Soc Health-Syst Pharm. 2024;41(2):142\u201350. https:\/\/doi.org\/10.32429\/jkshp.2024.41.2.004.","journal-title":"J Korean Soc Health-Syst Pharm"},{"key":"1895_CR22","unstructured":"A multi-centre, randomized, double-blind, double-dummy, parallel-group, phase 4 efficacy and safety study of P-CAB (Tegoprazan 50 mg Once Daily) compared With PPI (Rabeprazole 20 mg Once Daily) to reduce upper gastrointestinal events including bleeding and symptomatic ulcer disease 2020 [cited Duk-Woo Park, MD Recruiting]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04416581. Accessed 15 Oct 2024."},{"key":"1895_CR23","unstructured":"A randomized, open-label, three-period, multiple dosing crossover clinical trial to evaluate the influence of tegoprazan on the pharmacodynamics of clopidogrel in healthy subjects 2023 [cited HK inno.N Corporation Not yet recruiting]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06164834. Accessed 15 Oct 2024."},{"issue":"1","key":"1895_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jjcc.2020.02.012","volume":"76","author":"K Tsujita","year":"2020","unstructured":"Tsujita K, Deguchi H, Uda A, et al. Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: a nationwide database study. J Cardiol. 2020;76(1):51\u20137. https:\/\/doi.org\/10.1016\/j.jjcc.2020.02.012.","journal-title":"J Cardiol"},{"issue":"5","key":"1895_CR25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/cpt.863","volume":"103","author":"T Kagami","year":"2018","unstructured":"Kagami T, Yamade M, Suzuki T, et al. Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype. Clin Pharmacol Ther. 2018;103(5):906\u201313. https:\/\/doi.org\/10.1002\/cpt.863.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1895_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jcin.2023.01.363","volume":"16","author":"SH Lee","year":"2023","unstructured":"Lee SH, Jeong YH, Hong D, et al. Clinical impact of CYP2C19 genotype on clopidogrel-based antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2023;16(7):829\u201343. https:\/\/doi.org\/10.1016\/j.jcin.2023.01.363.","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"1895_CR27","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurheartj\/ehw525","volume":"38","author":"M Valgimigli","year":"2017","unstructured":"Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017;38(11):804\u201310. https:\/\/doi.org\/10.1093\/eurheartj\/ehw525.","journal-title":"Eur Heart J."},{"issue":"2","key":"1895_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.12997\/jla.2022.11.2.103","volume":"11","author":"DS Kyoung","year":"2022","unstructured":"Kyoung DS, Kim HS. Understanding and utilizing claim data from the korean national health insurance service (NHIS) and Health insurance review & assessment (HIRA) database for research. J Lipid Atheroscler. 2022;11(2):103\u201310. https:\/\/doi.org\/10.12997\/jla.2022.11.2.103.","journal-title":"J Lipid Atheroscler."},{"key":"1895_CR29","doi-asserted-by":"publisher","unstructured":"Lee YJ, Je NK. Evolving trends in acid suppression therapy among patients undergoing dual antiplatelet therapy: a Nationwide study in South Korea from 2018 to 2022. Br J Clin Pharmacol. 2025. https:\/\/doi.org\/10.1111\/bcp.16398.","DOI":"10.1111\/bcp.16398"},{"issue":"1","key":"1895_CR30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52773","volume":"16","author":"MS Bhatnagar","year":"2024","unstructured":"Bhatnagar MS, Choudhari S, Pawar D, et al. Long-Term use of proton-pump inhibitors: unravelling the safety puzzle. Cureus. 2024;16(1): e52773. https:\/\/doi.org\/10.7759\/cureus.52773.","journal-title":"Cureus"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01895-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T08:30:37Z","timestamp":1757665837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01895-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1895"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01895-2","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}